정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 786 | Not yet recruiting | Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen] | Covid19 | Drug: Ivermectin Drug: Placebo |
Phase 3 | Infectopharm Arzneimittel GmbH, GKM Gesellschaft fur Therapieforschung mbH | INDUSTRY | 412 | All | 18 Years | |
| 785 | Terminated | PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds | Covid-19 | Drug: Hydroxychloroquine Sulfate Regular dose Drug: Hydroxychloroquine Sulfate Loading Dose Drug: Chloroquine Drug: Placebo |
Phase 4 | Government of Punjab, Specialized Healthcare and Medical Education Department, Mayo Hospital Lahore, Services Hospital, Lahore, Pakistan Kidney and Liver Institute | OTHER_GOV | 137 | All | 20 Years ~ 50 Years | Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan Services Hospital, Lahore, Punjab, Pakistan |
| 784 | Recruiting | Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation | COVID | Drug: Propranolol Hydrochloride | Phase 3 | Ottawa Hospital Research Institute, Hamilton Health Sciences Corporation, Toronto General Hospital, University Health Network, Toronto, The Ottawa Hospital, McMaster University, Sinai Health System | OTHER | 108 | All | 19 Years | Hamilton Health Sciences Centre - Hamilton General Hospital, Hamilton, Ontario, Canada The Ottawa Hospital, Ottawa, Ontario, Canada |
| 783 | Active, not recruiting | Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection | Advanced or Metastatic Hematological or Solid Tumor | Drug: Autophagy inhibitor (GNS651) Other: Standard of care Drug: Avdoralimab Drug: Monalizumab |
Phase 2 | Centre Leon Berard | OTHER | 219 | All | 18 Years | Centre Leon Berard, Lyon, Rhone, France CHU Clermont Ferrand, Clermont Ferrand, France Centre Jean Perrin, Clermont-Ferrand, France Centre Oscar Lambret, Lille, France AP-HP Hopital Saint Antoine, Paris, France AP-HP La Pitie Salpetriere, Paris, France Hopital Saint-Joseph, Paris, France AP-HP Tenon, Paris, France AP-HP Hopital Bichat Claude Bernard, Paris, France GH Diaconesses Croix Saint Simon, Paris, France Institut de cancerologie Strasbourg Europe (ICANS), Strasbourg, France Institut Gustave Roussy, Villejuif, France |
| 782 | Active, not recruiting | Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19) | SARS-CoV-2 | Drug: Hydroxychloroquine | Phase 2 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, University of Bologna | OTHER | 2300 | All | 18 Years | Irst Irccs, Meldola, FC, Italy |
| 781 | Recruiting | Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 | Covid19 | Drug: Sacubitril / Valsartan Oral Tablet [Entresto] Drug: Placebo |
Phase 2 | Duke University, Novartis Pharmaceuticals | OTHER | 50 | All | 18 Years | Duke University Medical Center, Durham, North Carolina, United States |
| 780 | Enrolling by invitation | Protective Effect of Aspirin on COVID-19 Patients | Treatment | Drug: Aspirin 100mg | Phase 3 | Xijing Hospital | OTHER | 128 | All | 18 Years ~ 85 Years | Cai Yue, Xi'an, Shaanxi, China |